AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group

医学 诱导化疗 内科学 阿糖胞苷 奥佐美星 累积发病率 中期分析 肿瘤科 化疗 诱导疗法 柔红霉素 临时的 置信区间 外科 入射(几何) 移植 造血细胞 造血干细胞移植 化疗方案 新辅助治疗 随机对照试验 临床试验 总体生存率 护理标准 奥沙利铂 白血病 养生 维持疗法 队列 依托泊苷
作者
Jessica Anne Pollard,Todd A. Alonzo,Robert B. Gerbing,Matthew A. Kutny,Betsy Hirsch,Gordana Raca,Kasey Joanne Leger,Jennifer Jill Wilkes,Reena Pabari,Aman Wadhwa,Zachary T. Graff,Samir B. Kahwash,Karen M. Chisholm,Joseph H. Chewning,John T. Horan,Richard Aplenc,Andrew E. Place,Sarah Kathleen Tasian,Katherine Tarlock,Sarah Menig
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (27): 2590-2601 被引量:1
标识
DOI:10.1200/jco-25-02979
摘要

PURPOSE The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562 ) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with newly diagnosed AML. We hypothesized that CPX-351 given during induction 1 and 2 would improve outcomes compared with DA. PATIENTS AND METHODS Patients (21 years and younger) were randomly assigned to two cycles of DA induction (arm A = DA) or CPX-351 (arm B = CPX-351). All patients also received gemtuzumab ozogamicin in induction 1. Postinduction chemotherapy was according to risk assignment made at the end of induction 1 (EOI1). Those with high-risk (HR) AML received consolidation with allogeneic hematopoietic stem-cell transplantation (HSCT), whereas low-risk (LR) patients received chemotherapy alone. Protocol-specified interim analysis monitored efficacy and futility of CPX-351 induction with respect to the primary end point, event-free survival (EFS) from study entry. Disease-free survival (DFS) was calculated to determine the impact of EOI1 risk assignment. RESULTS Seven hundred twenty-one eligible patients with FLT3 wild-type AML were randomly assigned to DA (n = 358) or CPX-351 (n = 363). Interim analysis determined that the futility monitoring rule was crossed because of inferior EFS in the CPX-351 arm and the random assignment was stopped. The two-year EFS from study entry was 62.2% for DA versus 51.2% for CPX-351 ( P = .011). DFS for patients with HR AML was comparable for both arms. However, DFS was significantly lower and cumulative incidence of relapse (CIR) was higher for LR patients assigned to CPX-351 versus DA (2-year DFS from EOI1: DA: 73.8% v CPX-351 57.5% [ P = .001]; 2-year CIR Arm DA: 23.6% v CPX-351: 39.9% [ P = .001]). CONCLUSION CPX-351 was inferior to DA induction in the AAML1831 trial with differential EFS largely driven by events in LR patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mor完成签到 ,获得积分10
1秒前
Jzag完成签到 ,获得积分10
1秒前
cyan完成签到 ,获得积分10
1秒前
爱搞科研的壮壮完成签到 ,获得积分10
1秒前
Fengzhen007完成签到,获得积分10
2秒前
Sicily完成签到,获得积分10
2秒前
2秒前
LXL完成签到 ,获得积分10
3秒前
3秒前
饱满芷卉完成签到,获得积分10
4秒前
义气花生完成签到,获得积分10
4秒前
宝石山完成签到,获得积分10
6秒前
hugefrog完成签到,获得积分10
6秒前
7秒前
7秒前
不穷知识完成签到,获得积分10
8秒前
濮阳盼曼完成签到,获得积分0
8秒前
jiejie完成签到,获得积分10
8秒前
耸耸完成签到 ,获得积分10
9秒前
zq完成签到 ,获得积分10
9秒前
9秒前
JSEILWQ完成签到 ,获得积分10
9秒前
科研通AI6.4的应助被zhhl2006采纳,获得10
10秒前
特特特特特完成签到,获得积分10
10秒前
老毕完成签到,获得积分10
11秒前
彩色完成签到,获得积分10
11秒前
gcl完成签到,获得积分10
11秒前
Sweety完成签到,获得积分10
11秒前
小小酥被卷了完成签到,获得积分10
11秒前
胡杨完成签到,获得积分10
12秒前
今天值班的不是我完成签到,获得积分10
12秒前
的法国队完成签到,获得积分10
12秒前
yang的应助被龙抬头采纳,获得10
12秒前
zheng发布了新的文献求助10
13秒前
LU完成签到,获得积分10
14秒前
WY完成签到 ,获得积分10
14秒前
科研通AI6.4的应助被初景采纳,获得10
14秒前
兴奋鼠标完成签到 ,获得积分10
14秒前
chenamy完成签到,获得积分10
16秒前
木染完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173417
求助须知:如何正确求助?哪些是违规求助? 9565672
关于积分的说明 21781022
捐赠科研通 7767561
什么是DOI,文献DOI怎么找? 3431575
关于科研通互助平台的介绍 2555853
邀请新用户注册赠送积分活动 2476763